Jim Cramer Defends Eli Lilly and Company (LLY) Amid Concerns Over Drug Adherence, Cites Long-Term Health Potential
We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...
BIOA INVESTORS: Kirby McInerney LLP Reminds BioAge Labs, Inc. Investors of Important Deadline and Encourages Investors to Contact the Firm
January 30, 2025) - The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of ...
BioNTech SE (BNTX) Receives a Buy from Morgan Stanley
In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...
Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...